このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Lytix Biopharma 将来の成長

Future 基準チェック /26

Lytix Biopharmaは収益が増加すると予測されています。

主要情報

n/a

収益成長率

n/a

EPS成長率

Biotechs 収益成長	0.04%
収益成長率	120.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	29 Aug 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

OB:LYTIX - アナリストの将来予測と過去の財務データ ( )NOK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	232	N/A	N/A	213	1
12/31/2025	23	N/A	N/A	-33	1
12/31/2024	6	N/A	N/A	-75	1
6/30/2024	14	-76	-87	-87	N/A
3/31/2024	15	-86	-101	-101	N/A
12/31/2023	4	-88	-96	-96	N/A
9/30/2023	14	-99	-95	-95	N/A
6/30/2023	11	-91	-78	-78	N/A
3/31/2023	11	-61	-55	-55	N/A
12/31/2022	11	-56	-53	-53	N/A
9/30/2022	8	-43	-38	-38	N/A
6/30/2022	3	-51	106	106	N/A
3/31/2022	4	-63	-56	-56	N/A
12/31/2021	19	-48	-45	-45	N/A
9/30/2021	4	-44	-39	-39	N/A
6/30/2021	7	-40	-185	-185	N/A
3/31/2021	6	-35	-25	-25	N/A
12/31/2020	4	-42	-24	-24	N/A
12/31/2019	6	-33	-37	-37	N/A
12/31/2018	12	-62	-73	-73	N/A
12/31/2017	14	-69	N/A	-70	N/A

アナリストによる今後の成長予測

収入対貯蓄率: LYTIXの予測収益成長が貯蓄率 ( 2.1% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: LYTIXの収益がNorwegian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: LYTIXの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: LYTIXの収益 ( 110.7% ) Norwegian市場 ( 1.3% ) よりも速いペースで成長すると予測されています。

高い収益成長: LYTIXの収益 ( 110.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: LYTIXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Lytix Biopharma 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

New major risk - Financial position

New major risk - Share price stability

New minor risk - Shareholder dilution

Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer (Melanoma) Representing A Significant Commercial Opportunity

Lytix Biopharma AS has filed a Follow-on Equity Offering in the amount of NOK 55.071362 million.

Lytix Biopharma AS has filed a Follow-on Equity Offering in the amount of NOK 55.071362 million.

Full year 2023 earnings released

We're A Little Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Lytix Biopharma AS to Report Q4, 2023 Results on Feb 15, 2024

Lytix Biopharma as Announces Encouraging Results from ATLAS-It-04 Study Published in Oncoimmunology

Third quarter 2023 earnings released

We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

New major risk - Financial position

Lytix Biopharma AS Completes Recruitment of 20 Patients in the ATLAS-IT-05 Trial

Lytix Biopharma's Licensing Partner Verrica Pharmaceuticals Inc. Reports Interim Phase 2 Data with LTX-315

We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

Full year 2022 earnings released

Companies Like Lytix Biopharma (OB:LYTIX) Are In A Position To Invest In Growth

Lytix Biopharma AS to Report Fiscal Year 2022 Results on Mar 30, 2023

Third quarter 2022 earnings released

High number of new and inexperienced directors

Lytix Biopharma Announces Site Activation for the ATLAS-IT-05 Study in Three European Countries

Lytix Biopharma AS Presents Compelling Data in Collaboration with Research Groups At National Cancer Institute and Weill Cornell Medicine, USA

Lytix Biopharma AS Announces Approval to Expand the ATLAS-IT-05 Study to Europe

Lytix Biopharma AS Appoints Stephen Worsley as Chief Business Officer

Co-Founder & CEO recently bought kr100k worth of stock

Lytix Biopharma AS Announces Data from Its Atlas-It-04 Trial in Patients with Progressive Metastatic Soft Tissue Sarcoma

We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Lytix Biopharma as Announces That LTX-315 with Adoptive Cell Therapy Has Been Shown to Generate Tumor-Specific T Cells and Stabilize the Disease in Patients with Metastatic Soft Tissue Sarcoma (STS)

Less than half of directors are independent

Full year 2021 earnings: Revenues in line with analyst expectations

Lytix Biopharma announces Grant of 3 Million NOK from Oslo Regional Research Fund

We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Third quarter 2021 earnings: Revenues in line with analyst expectations

We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

Lytix Biopharma Initiates Phase II Combination Study in the US with LTX-315 and Pembrolizumab in Patients with Solid Tumors

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘